

DR. KATHRYN MCGONIGLE

PUBLICATIONS

Book Chapters

1. **McGonigle KF**, Huggins GR. Oral contraceptives and breast disease. In: Stoll BA, ed. Approaches to Breast Cancer Prevention. Netherlands: Kluwer Academic Publishers, 1991.
2. **McGonigle KF**, Lagasse LD, Karlan BY. Ovarian, uterine and cervical cancer in the elderly woman. In: Kaider FE, ed. Clinics in Geriatric Medicine. Philadelphia: WB Saunders Co., 1993
3. Huggins GR, **McGonigle KF**, Zucker P. Oral contraceptive use and neoplasia. In: Wallach EE, Zacur HA, eds. Reproductive Medicine and Surgery. St. Louis: Mosby-Year Book, 1995.
4. **McGonigle KF**, Huggins GR. Choosing hormonal contraception. In: Stoll BA, ed. Reducing Breast Cancer Risk in Women. Netherlands: Kluwer Academic Publishers, 1995.
5. **McGonigle KF**. Radiation associated bowel complications. In: Vasilev SA, ed. Perioperative Care in Gynecologic Oncology: Evidence-Based Management. John Wiley and Sons, 2000.
6. **McGonigle KF**, Lagasse LD. Perioperative care in the management of vulvar cancer. In: Vasilev SA, ed. Perioperative care in gynecologic oncology: Evidence-Based Management. John Wiley and Sons, 2000.
7. Kupferman S, **McGonigle KF**. Evaluation of Adnexal Masses & Screening for Ovarian Cancer. In: Lemcke D, Pattison J, Marshal LA, Cowley DS, eds. Current Care of Women: Diagnosis and Treatment. Lange Medical Books, McGraw-Hill, New York, 2004.

Other Journal Articles and Reviews

1. **McGonigle KF**, Huggins GR. Tubal sterilization: epidemiology of regret. Contemp Obstet Gynecol 35:15, 1990.
2. **McGonigle KF**, Berek JS. Early-stage squamous cell and adenocarcinoma of the cervix. Curr Opin Obstet Gynecol 4:109, 1992.
3. **McGonigle KF**. How oral contraceptives affect breast disease. Contemp Obstet Gynecol 37:156, 1992.
4. **McGonigle KF**. How progestins reduce endometrial cancer risk in ERT users. Contemp Obstet Gynecol 42:96-108, 1997.
5. Yamada SD, **McGonigle KF**. Cancer of the endometrium and corpus uteri. Curr Opin Obstet Gynecol 10:57-60, 1998.

6. Chen LM, **McGonigle KF**, Berek JS. Endometrial Cancer: Recent Developments in Evaluation and Treatment. *Oncology* 13:1665-1682, 1999

Images

1. Barsky SH, McGonigle K. Images in clinical medicine. Pseudomyxoma peritonei. *N Engl J Med* 350: e13, 2004.

Book Review

McGonigle KF Reviewed book entitled, "Endometrial Carcinoma and Precursors: Diagnosis and Treatment." Mencaglia L, Valle RF and Lurain J (eds) – ISIS Medical Media Limited – Oxford, England – *Oncology* 14(1):116.

Peer Reviewed Journal Articles

1. Golbus MS, **McGonigle KF**, Goldberg JD, Filly RA, Callen PW, Anderson RL. Fetal tissue sampling: the San Francisco experiences of 190 pregnancies. *West J Med* 150:423, 1989.
2. **McGonigle KF**, Huggins GR. Oral contraceptives and breast disease. *Fertil Steril* 56:799, 1991.
3. **McGonigle KF**, Dudzinski MR. Case Report: endometrial carcinoma of the ovary presenting with an enlarged inguinal lymph node without evidence of abdominal carcinomatosis. *Gynecol Oncol* 45:225, 1992.
4. **McGonigle KF**, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd HL. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. *Gynecol Oncol* 55:126, 1994.
5. Vasilev SA, **McGonigle KF**, Spencer-Smith L. Intestinal peritoneal sling as an adjuvant to radical pelvic surgery and/or adjuvant irradiation. *J Am Coll Surg* 180:568, 1994.
6. Vasilev SA, **McGonigle KF**. Extraperitoneal laparoscopic para-aortic lymph node dissection in a pig model: development of a technique. *J Lapar Surg* 5(2):85, 1995.
7. **McGonigle KF**, Lavey RH, Juillard GJF, Berek JS: Complications of radiation therapy for gynecologic malignancies in elderly women. *Int J Gyn Cancer* 6:149, 1996.
8. **McGonigle KF**, Lantry SA, Odom-Maryon TL, Chai Akiko, Vasilev SA, Simpson JF: Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. *Cancer Letters* 101:59, 1996.
9. Vasilev SA, **McGonigle KF**: Extraperitoneal laparoscopic para-aortic lymph node dissection. *Gynecol Oncol* 61:315, 1996.
10. McMeekin DS, **McGonigle KF**, Vasilev SA. Cervical cancer prevention: Toward cost-effective screening. *Medscape Women's Health* 2(12), 1997.

11. **McGonigle KF**, Shaw S, Vasilev SA, Odom-Maryon TL, Roy S, Simpson JF. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. *Am J Obstet Gynecol* 178(6):1145-50, 1998.
12. Morgan RJ, Newman EM, Doroshov JH, **McGonigle KF**, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetics analysis. *Cancer Res.* 1998;58:2793-800.
13. Gil B, Simpson JF, Somlo G, **McGonigle KF**, Wilczynski SP. Effects of tamoxifen on the cytology of the uterine cervix in breast cancer patients. *Diagn Cytopath* 19:417-422, 1998.
14. Monk BJ, Fowler JM, Burger RA, **McGonigle KF**, Eddy GI, Montz FJ. Expanded polytetrafluoroethylene is an effective barrier in preventing pelvic adhesions after radical surgery for ovarian carcinoma. *Int J Gynecol Oncol* 8:403-408, 1998
15. **McGonigle KF**, Vasilev SA, Odom-Maryon TL, Simpson JF. Ovarian histopathology in breast cancer patients receiving tamoxifen. *Gynecol Oncol* 73:402-406, 1999.
16. Brewster WR, DiSaia PJ, Grosen EA, **McGonigle KF**, Kuykendall JL, Creasman WT. An experience with estrogen replacement therapy in breast cancer survivors. *Int J Fertil* 44(4):186-192, 1999.
17. Morgan RJ, Doroshov JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W, Vasilev S, **McGonigle K**, Yen Y. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. *Bone Marrow Transplant* 28(9):859-63, 2001.
18. O'Connell JT, Tomlinson JS, Roberts AA, **McGonigle KF**, Barsky SH. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. *Am J Pathol* 161(2):551-64, 2002.
19. Elkas JC, Holschneider CH, Katz B, Li AJ, Pharm RL **McGonigle KF**, Berek JS. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. *Int J. Gynecol CA* 13:138-141, 2003.
20. Muntz H, Goff B, **McGonigle KF**, Isaacson C. The significance of psommoma bodies in screening cervical cytologic smears. *Am J Obset Gynecol* 188:1609-14,2003.
21. Morgan RJ, Synold T, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, **McGonigle KF**, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshov JH. Phase II trials of carboplatin and infusional cyclosporine with or without alpha-interferon in recurrent ovarian, fallopian tube or primary peritoneal cancer. *Cancer Chemother Pharmacol* 54:283-9, 2004.

22. Begley, JS, Kupferman, SP, Kuznetsov DD, Kobashi KC, Govier FE, **McGonigle KF**, Muntz HG. Incidence and management of sacrocolpopexy mesh erosions. *Am J Obstet Gynecol* 192:1956-62,2005.
23. Govier FE, Kobashi KC, Kozlowski PM, Kuznetsov DD, Begley SJ, **McGonigle KM**, Muntz HG. High complication rate identified in sacrocolpopexy patients attributed to silicone mesh. *Urology* 65:1099-1103,2005.
24. Ellenhorn JDI, Smith DD, Schwartz RE, Kawachi MH, Wilson TG, **McGonigle KF**, Wagman LD, Paz IB. Paint-only is equivalent to scrub-and-paint in preoperative preparation of abdominal surgery sites. *J Am Coll Surg* 201:737-741,2005.
25. **McGonigle KF**, Smith DD, Marx HF, Morgan RJ, Vasilev SA, Roy S, Morgan RJ, Wong PT, Simpson JF, Wilczynski SP. Uterine effects of tamoxifen: a prospective study. *Int J Gynecol Cancer*. 16 (2): 814-820, 2006.
26. Morgan RJ, Synold TV, Gandara D, Muggia F, Scudder S, Reed R, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, **McGonigle K**, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. *Int J Gynecol Cancer*. 17:373-378, 2007.

Letters to the Editor

1. **McGonigle KF**, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF. Response to Letter to the Editor titled Ultrasonographic evaluation of endometrial pathologies in postmenopausal breast cancer patients with tamoxifen treatment) Response was to this article: *Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy*. *Am J Obstet Gynecol* 178(6):1145-50, 1998.

Abstracts and Posters

1. Bellantoni MF, Harman SM, Vittone JL, Bryant L, Bass KM, Cotrell E, Copley CJ, **McGonigle KF**, Blackman MR. Android body habitus is associated with decreased growth hormone secretion in postmenopausal women. Oral presentation. The American Federation for Clinical Research, Baltimore, Maryland, May 1992.
2. **McGonigle KF**, Karlan BY, Barbuto DA, Chen D, Lagasse LD, Judd HL. Endometrial cancer developing in women on combination estrogen and progestin therapy - a retrospective analysis. Post presentation. American College of Obstetricians and Gynecologists (ACOG) Annual Meeting, Washington, DC, May 1993.
3. Bellantoni M, Vittone J, Bass K, **McGonigle KF**, Davidoff A, Haszard S, Harman SM, Tobin J, Blackman M. Low dose daily estrogen and progestin therapy in older postmenopausal women. Gerontological Society of America 47th Annual Society Meeting, Atlanta, Georgia, November 1994.

4. **McGonigle KF**, Simpson JF, Gill BL, Maryon TL, Wilzcynski SP, Vasilev SA. Uterine pathology in breast cancer patients on Tamoxifen. American Society of Clinical Oncology (ASCO), Dallas, Texas, May 1994.
5. Vasilev SA, **McGonigle KF**. Extraperitoneal laparoscopic para-aortic lymph node dissection: development of a technique. Society of Gynecologic Oncology (SGO), San Francisco, California, February 1995.
6. Morgan R, Kevecz R, Doroshow JH, Newman E, Carroll M, Coluzzi P, Leong L, Shibata S, Chow W, Vasilev S, **McGonigle KF**. Effects of intravenous (IV) calcium leucovorin (LV) on tumor cell incorporation of intraperitoneal (IP) iododeoxyuridine (IUDR): flow cytometric analysis. American Society of Clinical Oncology (ASCO), Los Angeles, California, May 1995.
7. **McGonigle KF**, Vasilev SA, Simpson JF. Ovarian pathology in breast cancer patients on Tamoxifen. American Society of Clinical Oncology (ASCO), Los Angeles, California, May 1995.
8. Morgan R, Doroshow JH, Newman E, Carroll M, Coluzzi P, Leong L, Shibata S, Chow W, Vasilev S, **McGonigle KF**, Margolin K, Somlo G, Raschko J, Tetef M, et al. High dose VP16, cyclophosphamide, infusional doxorubicin, with autologous bone marrow and peripheral blood stem cell support in patients with ovarian cancer. American Society of Clinical Oncology (ASCO), Los Angeles, California, May 1996.
9. **McGonigle KF**, Marx HF, Maryon TL, Roy S, Vasilev SA, Simpson JF. The uterine effects of tamoxifen: a prospective study. Society of Gynecologic Oncologists (SGO), Phoenix, Arizona, March 22-26, 1997.
10. Brewster WR, Grosen E, Kykendall JL, **McGonigle KF**, DiSaia PJ. Estrogen replacement therapy in breast cancer survivors. Society of Gynecologic Oncologists (SGO), Phoenix, Arizona, March 22-26, 1997.
11. **McGonigle KF**, Shaw SL, Vasilev SA, Roy S, Simpson JF. Effectiveness of transvaginal ultrasound in detecting endometrial pathology in breast cancer patients receiving tamoxifen. The American College of Obstetricians and Gynecologists (ACOG), Las Vegas, Nevada, April 1997.
12. Brewster WR, Grosen E, Kykendall JL, **McGonigle KF**, DiSaia PJ. Estrogen replacement therapy in breast cancer survivors. Western Association of Gynecologic Oncologists (WAGO), Jasper, Alberta, Canada, June 1997.
13. **McGonigle KF**, Shaw SL, Vasilev SA, Roy S, Simpson JF. Effectiveness of transvaginal ultrasound in detecting endometrial pathology in breast cancer patients receiving tamoxifen. Pacific Coast Obstetrical and Gynecological Society, Coeur d'Alene, Idaho, September 1997.
14. **McGonigle KF**, Vasilev SA, Maryon T, Simpson JF. Ovarian pathology in breast cancer patients receiving tamoxifen. Western Association of Gynecologic Oncologists (WAGO), Napa Valley, CA, May, 1998.

15. Reynolds CA, Holschneider CH, Natarjan S, Munro MG, Lemus J, **McGonigle KF**. Toluidine blue for cervical cancer screening: a new use for an old tool. Society of Gynecologic Oncologists (SGO), 2001.
16. Muntz HG, **McGonigle KF** et al. Phase II study of intraperitoneal topotecan as consolidative therapy in patients with advanced ovarian, fallopian tube and peritoneal cancer. Western Association of Gynecologic Oncologists (WAGO), May, 2004.
17. Muntz HG, **McGonigle KF**, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in patients with advanced ovarian and and primary peritoneal cancer. Martha Rivkin Ovarian Cancer Research Meeting, Seattle, WA, September, 2004.
18. Muntz HG, **McGonigle KF**, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in patients with advanced ovarian and and primary peritoneal cancer. Society of Gynecologic Oncologists (SGO), March, 2005.
19. **McGonigle KF**, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Gray HJ, Malpass TW. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian or primary peritoneal cancer. Submitted to American Society of Clinical Oncology (ASCO), June 2008.